title: [HIS-based analysis of comorbid characteristics and combined treatment of Chinese and western medicine in patients with depressive disorder].
abstract: OBJECTIVE
  To understand the comorbid characteristics and distribution of combined treatment of Chinese and Western medicine in depressive patients.
  
  
  METHODS
  The descriptive statistic method and association rule were used to analyze the data from 19 general hospitals with 3-A level in China.
  
  
  RESULTS
  Among the depressive disorder, the most frequent co-morbid physical diseases included hypertension (24.67%), coronary heart disease (16.10%) and cerebral infarction (12.89%), and the proportion of comorbid changes with the increasing age, from 6.51% to 12.55%, 16.33% and 12.47% for hypertension; from 2.79% to 5.69%, 10.17% and 14.22% for coronary heart disease; from 3.72%, 6.27%, 7.70% and 12.25% for cerebral infarction. The use frequency of the antidepressants is 77.18%, and the use frequency of flupentixol & melitracen is 20.95%. The use frequency of Huoxue Huayu Tongluo of traditional Chinese medicine is 59.97%, with that of 27.91% for Ginkgo biloba extract The combined use frequency of Huoxue Huayu Tongluo of TCM and the antidepressants is the highest, especially for the combined use of Shuxuening injection and fluoxetine.
  
  
  CONCLUSIONS
  The most frequent comorbid diseases of depression include three kinds of diseases, such as hypertension, coronary heart disease and cerebral infarction, and its proportion gradually increased with the growth of age. The single use frequency of flupentixol & melitracen and G. biloba extract is the highest, while the combined use of Shuxuening injection and fluoxetine is the highest.
authors.forename: Jun-ran
authors.initials: JR
authors.lastname: Zheng
authors.forename: Yan-ming
authors.initials: YM
authors.lastname: Xie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000873:Anthracenes / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002681:China; D003131:Combined Modality Therapy / Q000379:methods; D003866:Depressive Disorder / Q000188:drug therapy*; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D005475:Flupenthixol / Q000627:therapeutic use; D020441:Ginkgo biloba / Q000737:chemistry; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000873:Anthracenes; D000928:Antidepressive Agents; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D010936:Plant Extracts; C000851:flupentixol, melitracen drug combination; C578963:shuxuening; C527174:tongluo; D005473:Fluoxetine; D005475:Flupenthixol